Creating new drugs to target estrogen receptors for glioblastoma treatment
Official title: Development of Potent Estrogen Receptor Beta Agonists for Treating Glioblastoma
Funded at University of Texas Hlth Science Center · NIH-11001201 · Data updated 2026-11-12
This study is looking for ways to use new medications that target a specific estrogen receptor to help treat glioblastoma, a tough type of brain cancer, while keeping side effects low, and patients may have a chance to join trials to see how well these new treatments work.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Texas Hlth Science Center NIH-funded |
| Lab location | 1 site (San Antonio, United States) |
| Project start | January 1, 2023 |
| Project end | December 31, 2027 |
| Funding year | 2025 |
| Award (this year) | $477,217 |
| NIH project number | 5R01CA269866-03 |
| Project ID | NIH-11001201 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for participation would include adults diagnosed with glioblastoma who are seeking new treatment options.
✕Less likely to help
Patients with glioblastoma who have already exhausted all treatment options or those with contraindications to estrogen therapies may not benefit from this research.
What this research studies
This research focuses on developing new and potent estrogen receptor beta (ERβ) agonists to treat glioblastoma, a highly aggressive brain cancer. The study aims to leverage the protective role of female sex hormones against cancer progression while minimizing the risks associated with traditional estrogen treatments. By utilizing advanced techniques, including CRISPR technology, the researchers will explore the therapeutic potential of selective ERβ agonists that can effectively suppress tumor growth without the adverse effects linked to existing treatments. Patients may have the opportunity to participate in trials assessing the safety and efficacy of these novel compounds.
Why it matters
Potential benefit: If successful, this research could lead to more effective and safer treatment options for glioblastoma patients.
How similar studies have gone: While the approach of targeting estrogen receptors in glioblastoma is relatively novel, previous studies have shown promise in using hormone-based therapies for other cancers.
Where this research is happening
-
University of Texas Hlth Science Center
San Antonio, United States Active
Researchers
- Principal investigator: Vadlamudi, Ratna K — University of Texas Hlth Science Center
- Study coordinator: Vadlamudi, Ratna K
Related research
Other NIH-funded projects on the same topics.
-
Small molecules to block Slit2/ROBO in glioblastoma
A study to test small molecule drugs that block Slit2/ROBO signals to help treat glioblastoma in patients.
-
Immunotherapy for glioblastoma: advancing treatment and understanding
A patient-friendly summary of a grant exploring new immune-based treatments for glioblastoma to improve options for people affected by this brain cancer.
-
Small-molecule and biologic treatments for glioblastoma using targeted brain delivery
A new approach aims to use FPS-ZM1 to shrink brain swelling and support immunotherapy for glioblastoma, potentially helping patients recover after surgery.
-
Targeted therapies for glioblastoma in adults and kids
A large NIH program is exploring new brain cancer therapies, including drugs that reach the brain and work against glioblastoma in both children and adults.
-
6-thio-2'-deoxyguanosine for glioblastoma: a new approach to target tumors before surgery
A trial tests a novel drug given before glioblastoma surgery to see how it behaves in the body and within the tumor, and to learn how it affects cancer cells and the immune environment.
-
CD38-Driven Changes in Brain Tumor Metabolism and Immunity in Glioblastoma
A patient-facing look at how scientists plan to study how glioblastoma grows by changing its metabolism and dampening the immune response, with potential targets to help treatment in the future.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.